We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Handheld Mass Spectrometry Probe Identifies Clinically Relevant Bacteria

By LabMedica International staff writers
Posted on 04 Oct 2022

Rapid identification of bacteria is critical to prevent antimicrobial resistance and ensure positive patient outcomes. More...

Identifying bacteria while a patient is still in surgery could allow doctors to more quickly move to a targeted antibiotic for their infection.

The Handheld Mass Spectrometry Probe consists of a handheld, disposable ionization device connected to a mass spectrometer. It works via ambient ionization, using drops of water to extract lipids and metabolites from tissue that are then analyzed via mass spectrometry to generate molecular profiles. These can be used to distinguish between different tissue types or, in the case of a recent study, different bacteria.

Medical Scientists at The University of Texas at Austin (Austin, TX, USA) and their colleagues used the MasSpec Pen (Genio Technologies, Jordan, UT, USA) on cultured samples to generate molecular profiles and develop classifiers. They analyzed 163 culture samples comprising 28 strains across eight bacterial species, including Staphylococcus aureus, Group A and B Streptococcus, and Kingella kingae. The effort focused on microorganisms commonly linked to pediatric osteoarticular infections. The system currently uses a Thermo Fisher Orbitrap Exploris 120 mass spectrometer (Thermo Fisher Scientific, Waltham MA, USA) and comes packaged as a mobile, battery-powered device that can be moved between different operating rooms.

The team then then tested these classifiers in a validation set consisting of 74 samples spanning 15 strains. In the validation work, they found that the pen was able to distinguish between Group A and B Streptococcus with 85% accuracy and between S. aureus and Staphylococcus epidermidis with 97% accuracy. The device identified a validation set of 24 samples of Gram-negative bacteria spanning six strains with accuracy of 92%. They then applied their classifiers to a set of five clinical samples taken from four patients with osteoarticular infections, exploring how the device performed in direct surgical specimens without culture. They were not able to identify the bacteria down to the species level, but were able to identify the Gram stain type and genus of the microbes in the different samples.

Livia Eberlin, PhD, associate professor of surgery and inventor of the MasSpec Pen, said, “We're centered in surgical applications, and one of the things we've been asked by a variety of surgeons, especially infectious disease surgeons, is whether we could identify bacteria when we were excising, for instance, infected bone.”

The authors concluded that the MasSpec Pen enables identification of several bacteria at different taxonomic levels in seconds from cultured samples and has potential for culture-independent identification of bacteria directly from clinical samples based on the detection of metabolic species. The study was published on September 14, 2022 in the journal Clinical Chemistry.

Related Links:
The University of Texas at Austin 
Genio Technologies 
Thermo Fisher Scientific 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automatic CLIA Analyzer
Shine i6000
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The test combines RNA signals from the tumor-immune microenvironment to predict treatment response, rather than relying on a single marker such as PD-L1 expression.(Image Credit: Adobe Stock)

RNA-Based Test Predicts Immunotherapy Response in Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) represents the largest U.S. patient population eligible for immune checkpoint inhibitor therapy. Treatment selection often relies on PD-L1 expression, but a single protein... Read more

Immunology

view channel
Image Credit: Adobe Stock

Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk

A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more

Industry

view channel
Image Credit: iStock

Global TB Summit Connects Diagnostic Testing With Prevention and Clinical Care

Tuberculosis remains a major global infectious disease challenge despite declining deaths. In 2024, an estimated 10.7 million people worldwide developed the disease and nearly 1.2 million died from it.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.